Literature DB >> 18256542

Mechanisms of MYC stabilization in human malignancies.

Melissa R Junttila1, Jukka Westermarck.   

Abstract

MYC is a pleiotropic transcription factor that has been linked to a diverse range of cellular functions, such as cell cycle regulation, proliferation, growth, differentiation and metabolism. Not surprisingly, aberrant MYC signaling has been observed in human cancers and MYC has been demonstrated to promote cell transformation and tumor progression. Here we discuss recent discoveries that have expanded our knowledge of MYC protein stability. In particular we focus on mechanisms that might explain the increased stability of MYC often observed in human cancers and cell lines. We also summarize our recent characterization of Cancerous inhibitor of PP2A (CIP2A(/KIAA1524)) as a protein that inhibits PP2A-mediated MYC dephosphorylation and proteolytic degradation. Finally, we discuss the potential relevance of mechanisms that regulate MYC stability for tumor formation in the context of cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18256542     DOI: 10.4161/cc.7.5.5492

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  68 in total

1.  A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.

Authors:  Zhaojun Qiu; Pengyan Fa; Tao Liu; Chandra B Prasad; Shanhuai Ma; Zhipeng Hong; Ernest R Chan; Hongbing Wang; Zaibo Li; Kai He; Qi-En Wang; Terence M Williams; Chunhong Yan; Steven T Sizemore; Goutham Narla; Junran Zhang
Journal:  Cancer Res       Date:  2020-06-10       Impact factor: 12.701

2.  Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Michelle Pusey; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-04-02

3.  Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Authors:  Kazuyuki Matsushita; Hideaki Shimada; Yasuji Ueda; Makoto Inoue; Mamoru Hasegawa; Takeshi Tomonaga; Hisahiro Matsubara; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells.

Authors:  Ion Cristóbal; Rebeca Manso; Raúl Rincón; Juan Madoz-Gúrpide; Cristina Caramés; Federico Rojo; Jesús García-Foncillas
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-15       Impact factor: 4.553

5.  MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Authors:  Andreas Pettersson; Travis Gerke; Kathryn L Penney; Rosina T Lis; Edward C Stack; Nelma Pértega-Gomes; Giorgia Zadra; Svitlana Tyekucheva; Edward L Giovannucci; Lorelei A Mucci; Massimo Loda
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

6.  Reduced c-myc expression levels limit follicular mature B cell cycling in response to TLR signals.

Authors:  Almut Meyer-Bahlburg; Ashok D Bandaranayake; Sarah F Andrews; David J Rawlings
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

7.  The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

Authors:  Cyril Sobolewski; Claudia Cerella; Mario Dicato; Lina Ghibelli; Marc Diederich
Journal:  Int J Cell Biol       Date:  2010-03-17

8.  The lethal giant larvae tumour suppressor mutation requires dMyc oncoprotein to promote clonal malignancy.

Authors:  Francesca Froldi; Marcello Ziosi; Flavio Garoia; Andrea Pession; Nicola A Grzeschik; Paola Bellosta; Dennis Strand; Helena E Richardson; Annalisa Pession; Daniela Grifoni
Journal:  BMC Biol       Date:  2010-04-07       Impact factor: 7.431

9.  Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert.

Authors:  Carmen Maffettone; Guohua Chen; Ignat Drozdov; Christos Ouzounis; Kostas Pantopoulos
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Authors:  Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.